Related Experiment Video

Updated: Jun 28, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Influence of the factor II G20210A variant or the factor V G1691A mutation on symptomatic recurrent venous

G Young1, S Becker, C Düring

  • 1Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, CA, USA.

Journal of Thrombosis and Haemostasis : JTH
|November 6, 2008
PubMed

Insights

The Factor II G20210A mutation increases the risk of recurrent venous thromboembolism (VTE) in children. This finding highlights the importance of genetic factors in pediatric VTE recurrence.

Area of Science:

  • Pediatric Hematology
  • Genetics
  • Thrombosis Research

Background:

  • Venous thromboembolism (VTE) is a significant concern in children.
  • Genetic mutations, such as Factor II (FII) G20210A and Factor V (FV) G1691A, are known risk factors for VTE.
  • The relative importance of these mutations in predicting VTE recurrence in pediatric populations requires further elucidation.

Purpose of the Study:

  • To compare the risk of recurrent VTE in children with FII G20210A or FV G1691A mutations.
  • To identify genetic predictors for fatal and non-fatal VTE recurrence in pediatric patients.

Main Methods:

  • A cohort study involving children aged newborn to 18 years with a history of VTE.
  • Patients were genotyped for FII G20210A and FV G1691A mutations.
  • VTE recurrence rates and time to recurrence were analyzed using Cox regression, adjusting for age and sex, with a control group of children without thrombophilia.

Main Results:

  • The study included 416 children; 44 experienced recurrent VTE.
  • Recurrence incidence rates were 57.9 per 1000 person-years for FII carriers, 17.9 for FV carriers, and 11.8 for controls.
  • Multivariate analysis indicated that the FII G20210A variant significantly increased the hazard for VTE recurrence (HR 2.6; 95% CI 1.1-5.9).

Conclusions:

  • The FII G20210A mutation is associated with an elevated risk of VTE recurrence in children.
  • Genetic predisposition plays a crucial role in the long-term outcomes of pediatric VTE.
Abstract

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...